RecruitingPhase 1NCT07276958

A Study of LY4298445 in Healthy Participants and Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA)

Studying Autosomal systemic lupus erythematosus

Last synced from ClinicalTrials.gov May 5, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Eli Lilly and Company
Principal Investigator: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)
Eli Lilly and Company
Intervention: LY4298445(drug)
Enrollment: 63 enrolled
Eligibility: 18-55 years · All sexes
Timeline: 2026 – 2028

Study locations (7)

Nucleus Network, Brisbane, Australia
Nucleus Network, Melbourne, Australia
Peking University First Hospital, Beijing, China
Peking University Third Hospital, Beijing, China
Xiangya Hospital of Central South University, Changsha, China
Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan, China

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07276958 on ClinicalTrials.gov

Other trials for Autosomal systemic lupus erythematosus

Additional recruiting or active studies for the same condition.

See all trials for Autosomal systemic lupus erythematosus →

← Back to all trials